Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Hutchmed (China) Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Hutchmed (China) Ltd is a mid-cap company with a market capitalization of $2.70B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For HCM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 13.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, HCM included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | HCM | Rank |
|---|---|---|
| Market Cap | $2.70B | 60/60 |
| P/E Ratio | 27.07x | 19/33 |
| P/B Ratio | 2.18x | 40/43 |
| EPS | $0.56 | – |
| Book Value/Share | $6.96 | – |
| Metric | HCM | Rank |
|---|---|---|
| ROIC | -5.8% | 26/45 |
| Operating Margin | -7.0% | 26/39 |
| EBT Margin | 48.1% | 4/46 |
| Tax Rate | 12.5% | – |
| Metric | HCM | Rank |
|---|---|---|
| Current Ratio | 4.96x | 16/58 |
| Quick Ratio | 4.83x | 2/43 |
| D/E Ratio | 0.41x | 32/48 |
| Financial Leverage | 1.42x | 31/48 |
| Interest Coverage | -14.2x | 24/34 |
| Working Capital | $1.25B | 23/58 |
| Metric | HCM | Rank |
|---|---|---|
| Operating Cash Flow | -$64M | 41/59 |
| Metric | HCM | Rank |
|---|---|---|
| Operating Income | -$83M | 31/51 |
| R&D Expense | $360M | 36/58 |
| SG&A Expense | $216M | 41/41 |
| Metric | HCM | Rank |
|---|---|---|
| Shares Outstanding | 178M | – |
| Total Current Assets | $1.57B | 89.4% of assets |
| Cash & Short-term Investments | $71M | 4.1% of assets |
| Accounts Receivable | $127M | 7.2% of assets |
| Inventory | $41M | 2.3% of assets |
| Total Liabilities | $502M | 28.6% of assets |
| Short-term Debt | $270M | 15.4% of assets |
Companies classified under the same SEC industry code as Hutchmed (China) Ltd (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| HCM Hutchmed (China) Ltd | $2.70B | |
| LLY Eli Lilly & Co | $1.28T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $514.78B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $288.97B | |
| ABT Abbott Laboratories | $191.15B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137.50B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.54B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $33.93B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $26.45B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.89B | |
| ASND Ascendis Pharma A/S | $16.86B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| ELAN Elanco Animal Health Inc | $12.86B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $10.85B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | |
| TGTX Tg Therapeutics, Inc. | $9.20B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.22B | |
| CORT Corcept Therapeutics Inc | $7.87B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| ALKS Alkermes Plc. | $7.70B | |
| ABVX Abivax S.A. | $7.50B | |
| CYTK Cytokinetics Inc | $7.46B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | |
| AXSM Axsome Therapeutics, Inc. | $6.93B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.43B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | |
| BLTE Belite Bio, Inc | $6.07B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.04B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.81B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its autoimmune hemolytic anemia medication sovleplenib was granted orphan drug designation by the US Food & Drug Administration.
HUTCHMED reported first-half 2025 revenue of $278 million, down 10% YoY, with net income reaching a record $455 million due to a partial JV divestment. ZECLA delivered 25% growth, but China sales for ...
Detailed price information for Hutchmed China Ltd ADR (HCM-Q) from The Globe and Mail including charting and trades.
Our AI scores Hutchmed (China) Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For HCM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 13.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Hutchmed (China) Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
60 issuers in our coverage, HCM included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
